BR9911145A - Composto, uso de um composto, composição farmacêutica, e, processo para tratamento de um mamìfero e para a preparação de compostos - Google Patents

Composto, uso de um composto, composição farmacêutica, e, processo para tratamento de um mamìfero e para a preparação de compostos

Info

Publication number
BR9911145A
BR9911145A BR9911145-4A BR9911145A BR9911145A BR 9911145 A BR9911145 A BR 9911145A BR 9911145 A BR9911145 A BR 9911145A BR 9911145 A BR9911145 A BR 9911145A
Authority
BR
Brazil
Prior art keywords
compound
treating
pharmaceutical composition
mammal
compounds
Prior art date
Application number
BR9911145-4A
Other languages
English (en)
Inventor
Romano Di Fabio
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812410.0A external-priority patent/GB9812410D0/en
Priority claimed from GBGB9812408.4A external-priority patent/GB9812408D0/en
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of BR9911145A publication Critical patent/BR9911145A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA TRATAMENTO DE UM MAMìFERO E PARA A PREPARAçãO DE COMPOSTOS" Compostos de fórmula (I) ou um sal ou um seu éster não tóxico metabolicamente lábil, em que Y representa um átomo de carbono; Z é o grupo CH, que é ligado ao grupo Y através de uma ligação dupla, e X é CH ou Z é metileno ou NR~ 11~, e X é um átomo de carbono ligado ao grupo Y através de uma ligação dupla; A representa uma cadeia alquileno C~ 1-2~, a qual pode ser substituída por um ou dois grupos selecionados de alquila C~ 1-6~ opcionalmente substituída por hidróxi, alquil C~ 1-4~ amino ou dialquil C~ 1-4~ amino, ou a qual pode ser substituída pela fenila opcionalmente substituída, um grupo heteroarila de 5 membros contendo de 1 a 3 heteroátomos selecionados de oxigênio, enxofre e nitrogênio ou, um grupo heteroarila de 6 membros contendo de 1 a 3 átomos de nitrogênio, processos para sua preparação e seu uso como antagonistas de glicina.
BR9911145-4A 1998-06-10 1999-06-08 Composto, uso de um composto, composição farmacêutica, e, processo para tratamento de um mamìfero e para a preparação de compostos BR9911145A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9812410.0A GB9812410D0 (en) 1998-06-10 1998-06-10 Heterocyclic derivatives
GBGB9812408.4A GB9812408D0 (en) 1998-06-10 1998-06-10 Heterocyclic compounds
PCT/EP1999/003936 WO1999064411A1 (en) 1998-06-10 1999-06-08 Tetrahydroquinoline derivatives as glycine antagonists

Publications (1)

Publication Number Publication Date
BR9911145A true BR9911145A (pt) 2001-03-06

Family

ID=26313826

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911145-4A BR9911145A (pt) 1998-06-10 1999-06-08 Composto, uso de um composto, composição farmacêutica, e, processo para tratamento de um mamìfero e para a preparação de compostos

Country Status (34)

Country Link
US (3) US6362199B1 (pt)
EP (1) EP1086093B1 (pt)
JP (1) JP2002517492A (pt)
KR (1) KR100586762B1 (pt)
CN (1) CN1173970C (pt)
AP (1) AP2000002008A0 (pt)
AR (1) AR018632A1 (pt)
AT (1) ATE301650T1 (pt)
AU (1) AU753867B2 (pt)
BG (1) BG105123A (pt)
BR (1) BR9911145A (pt)
CA (1) CA2334727C (pt)
CO (1) CO5080785A1 (pt)
CZ (1) CZ293605B6 (pt)
DE (1) DE69926632T2 (pt)
DK (1) DK1086093T3 (pt)
EA (1) EA003276B1 (pt)
EE (1) EE200000733A (pt)
ES (1) ES2249010T3 (pt)
HK (1) HK1034079A1 (pt)
HR (1) HRP20000845A2 (pt)
HU (1) HUP0102767A3 (pt)
ID (1) ID27845A (pt)
IL (2) IL140062A0 (pt)
IS (1) IS5746A (pt)
MY (1) MY125037A (pt)
NO (1) NO321904B1 (pt)
NZ (1) NZ508638A (pt)
OA (1) OA11564A (pt)
PE (1) PE20000724A1 (pt)
PL (1) PL197160B1 (pt)
TR (1) TR200003652T2 (pt)
TW (1) TWI229079B (pt)
WO (1) WO1999064411A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
CA2598133A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024516C1 (ru) * 1989-02-02 1994-12-15 Яманути Фармасьютикал Ко., Лтд. Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
IL93610A0 (en) * 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
CA2232509A1 (en) 1995-09-29 1997-04-10 Glaxo Wellcome Spa Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
HK1034079A1 (en) 2001-10-12
JP2002517492A (ja) 2002-06-18
US6413985B1 (en) 2002-07-02
KR100586762B1 (ko) 2006-06-08
NO20006227D0 (no) 2000-12-07
CA2334727C (en) 2009-08-04
CN1311785A (zh) 2001-09-05
IL140062A0 (en) 2002-02-10
DE69926632T2 (de) 2006-01-19
ID27845A (id) 2001-04-26
DE69926632D1 (de) 2005-09-15
ATE301650T1 (de) 2005-08-15
BG105123A (en) 2001-11-30
EE200000733A (et) 2002-06-17
PL197160B1 (pl) 2008-03-31
TR200003652T2 (tr) 2001-04-20
ES2249010T3 (es) 2006-03-16
IL140062A (en) 2007-05-15
AU753867B2 (en) 2002-10-31
EP1086093B1 (en) 2005-08-10
AP2000002008A0 (en) 2000-12-31
HUP0102767A3 (en) 2003-01-28
OA11564A (en) 2004-05-24
NO321904B1 (no) 2006-07-17
CN1173970C (zh) 2004-11-03
CZ20004587A3 (en) 2001-05-16
MY125037A (en) 2006-07-31
TWI229079B (en) 2005-03-11
EA003276B1 (ru) 2003-04-24
US6495566B2 (en) 2002-12-17
CO5080785A1 (es) 2001-09-25
CZ293605B6 (cs) 2004-06-16
DK1086093T3 (da) 2005-11-28
KR20010052722A (ko) 2001-06-25
PL344694A1 (en) 2001-11-19
IS5746A (is) 2000-11-30
WO1999064411A1 (en) 1999-12-16
NZ508638A (en) 2003-08-29
AR018632A1 (es) 2001-11-28
CA2334727A1 (en) 1999-12-16
HUP0102767A2 (hu) 2001-12-28
NO20006227L (no) 2001-02-08
AU4509299A (en) 1999-12-30
EA200001165A1 (ru) 2001-06-25
EP1086093A1 (en) 2001-03-28
HRP20000845A2 (en) 2001-10-31
US20020052391A1 (en) 2002-05-02
PE20000724A1 (es) 2000-08-17
US20020169186A1 (en) 2002-11-14
US6362199B1 (en) 2002-03-26

Similar Documents

Publication Publication Date Title
CZ15795A3 (en) Derivatives of hydroxamic acid, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
EA199900242A1 (ru) Аралкил- и аралкилиден-гетероциклические лактамы и имиды
BR9911145A (pt) Composto, uso de um composto, composição farmacêutica, e, processo para tratamento de um mamìfero e para a preparação de compostos
PT96324A (pt) Processo para a preparacao de compostos peptidicos e de composicoes farmaceuticas que os contem
ES539658A0 (es) Procedimiento de preparacion de nuevos derivados de la xan- tina y de sus sales de adicion con acidos apropiados
DE3881489D1 (de) Peptide mit collagenase hemmender wirkung.
ES2035824T3 (es) Procedimiento para preparar compuestos profarmacos y preparaciones que los contienen.
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
SE8604950L (sv) Demensforbettrande och terapeutiska medel
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
PT91607A (pt) Process for the preparation of substituted beta-diketones and of pharmaceutical compositions containing them
ES8404312A1 (es) Un procedimiento para la preparacion de derivados de etanolamina.
FI833647A0 (fi) Fenyl-indenderivat, deras syraadditionssalt och foerfarande foer deras framstaellning
KR920004402A (ko) 신규 퀴놀린 카르복실산 유도체, 상기 화합물 함유 항균제 및 상기 화합물 제조 방법
BR0013375A (pt) Composições farmacêuticas contendo derivados tiazolidinodiona e processo para sua preparação
DE69029814D1 (de) Inhibitoren der dihydrofolatreduktase von pneumocystis carinii
ES556048A0 (es) Un procedimiento para la preparacion de un derivado de tiazolidina.
BR9713618A (pt) Derivados da eritromicina, seu processo de preparo e sua aplicação como medicamentos
DE69016266D1 (de) Aminoketonverbindungen.
DE68906172D1 (de) Verwendung eines mittels zum foerdern des tierwachstums.
SE8303410D0 (sv) Benzene derivatives, processes for their preparation and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INC. CL:C07D 401/04; C07D 401/14; C07D 215/02; A61P 1/08; A61P 3/10; A61P 9/00; A61P 13/02; A61P 25/00; A61P 25/02; A61P 25/06; A61P 25/08; A61P 25/18; A61P 25/22; A61P 25/24; A61P 25/28; A61P 25/30; A61P 25/32; A61P 25/34; A61P 25/36.

Ipc: C07D 401/04 (2008.04), A61K 31/47 (2008.04), C07D

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE OA DISPOSTO NOS ARTIGOS 8O 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.